Who makes AT-501 Low Dose vaccine with Adjuvant?

AT-501 Low Dose vaccine with Adjuvant is developed by Medigen Vaccine Biologics Corp..

What development phase is AT-501 Low Dose vaccine with Adjuvant in?

AT-501 Low Dose vaccine with Adjuvant is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AT-501 Low Dose vaccine with Adjuvant

Medigen Vaccine Biologics Corp. · Phase 1 active Biologic

At a glance

Generic name	AT-501 Low Dose vaccine with Adjuvant
Sponsor	Medigen Vaccine Biologics Corp.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AT-501 Low Dose vaccine with Adjuvant CI brief — competitive landscape report
AT-501 Low Dose vaccine with Adjuvant updates RSS · CI watch RSS
Medigen Vaccine Biologics Corp. portfolio CI